KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Deffered Revenue (2016 - 2026)

Pacific Biosciences Of California has reported Non-Current Deffered Revenue over the past 15 years, most recently at $3.9 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 33.41% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 33.41%, while the annual FY2025 figure was $3.9 million, 33.41% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $3.9 million at Pacific Biosciences Of California, down from $4.4 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $25.2 million in Q1 2022 and troughed at $1.8 million in Q3 2022.
  • A 5-year average of $7.0 million and a median of $5.5 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: soared 1497.51% in 2021 and later crashed 92.84% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $25.0 million in 2021, then crashed by 92.84% to $1.8 million in 2022, then soared by 208.25% to $5.5 million in 2023, then rose by 6.69% to $5.9 million in 2024, then tumbled by 33.41% to $3.9 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for PACB at $3.9 million in Q4 2025, $4.4 million in Q3 2025, and $5.7 million in Q2 2025.